Novo's Ozempic, Wegovy picked for US Medicare price negotiations
Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for ...
devdiscourse12h
Medicare Price Negotiations Target Diabetes and Weight-loss Drugs
Novo Nordisk's Ozempic and Wegovy are among 15 drugs targeted for Medicare price negotiations in 2027. The U.S. aims to cut ...
FiercePharma11h
Novo's semaglutide among 2nd batch of drugs selected for IRA price negotiations
The U.S. government has selected the second batch of drugs up for Medicare price negotiations under the Inflation Reduction ...
BioSpace9h
Novo Nordisk Links High-Dose Wegovy to Increased Weight Loss in Phase III Trial
Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...
Novo Nordisk Unusual Options Activity
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...
Columbus joins national fight accusing drug manufacturers of inflating insulin prices
According to the American Diabetes Association, approximately 8.4 million people in the United States need insulin to survive ...
LVMH overtakes Novo Nordisk as Europe’s most valuable company
Luxury bellwether regains crown as drugmaker slips on concerns it will have to cut weight loss medication prices in US ...
Novo Nordisk’s Semaglutide 7.2mg s.c. achieved 21% weight loss in STEP UP trial
Novo Nordisk (NVO) announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a ...
Finally An Attractive Entry Point Into Novo Nordisk
Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...